Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We tried to identify the target/s of autoantibodies to basal ganglia neurons found in a patient with hyperkinetic movement disorders (HMD) characterized by rapid, rhythmic involuntary movements or spasms in both face and neck. Patient and control sera were used in Western blot to probe mouse brain homogenates. Two-dimensional gel electrophoresis (2-DE) SDS-PAGE protein spots recognized by the patient's antibodies were excised and sequenced by mass spectrometry analysis, and the glycolytic enzyme aldolase A was identified as the antigen recognized by the patient's autoantibodies. To assess relevance and specificity of these antibodies to the identified targets as biomarkers of autoimmunity in movement disorders, autoantibody responses to the identified target were then measured by ELISA in various diseases of the central nervous system. Anti-aldolase A autoantibodies were associated mainly with HMD (7/17, 41%) and Parkinson's disease (4/30, 13%) patients, and undetectable in subjects with other inflammatory and non-inflammatory central nervous system diseases. We, thus, identified aldolase A as an autoantigen in a sub-group of patients with HMD, a clinically ill-defined syndrome. Anti-aldolase A antibodies may represent a useful biomarker of autoimmunity in HMD patients.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalNeurological Sciences
Volume34
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Fructose-Bisphosphate Aldolase
Movement Disorders
Autoantibodies
Proteomics
Hyperkinesis
Central Nervous System Diseases
Autoimmunity
Biomarkers
Antibody Specificity
Antibodies
Dyskinesias
Electrophoresis, Gel, Two-Dimensional
Autoantigens
Spasm
Basal Ganglia
Parkinson Disease
Polyacrylamide Gel Electrophoresis
Mass Spectrometry
Neck
Western Blotting

Keywords

  • Aldolase A
  • Hyperkinetic movement disorders
  • SERPA

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

@article{19f279d171be488094d16b4da06cd4ea,
title = "Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders",
abstract = "We tried to identify the target/s of autoantibodies to basal ganglia neurons found in a patient with hyperkinetic movement disorders (HMD) characterized by rapid, rhythmic involuntary movements or spasms in both face and neck. Patient and control sera were used in Western blot to probe mouse brain homogenates. Two-dimensional gel electrophoresis (2-DE) SDS-PAGE protein spots recognized by the patient's antibodies were excised and sequenced by mass spectrometry analysis, and the glycolytic enzyme aldolase A was identified as the antigen recognized by the patient's autoantibodies. To assess relevance and specificity of these antibodies to the identified targets as biomarkers of autoimmunity in movement disorders, autoantibody responses to the identified target were then measured by ELISA in various diseases of the central nervous system. Anti-aldolase A autoantibodies were associated mainly with HMD (7/17, 41{\%}) and Parkinson's disease (4/30, 13{\%}) patients, and undetectable in subjects with other inflammatory and non-inflammatory central nervous system diseases. We, thus, identified aldolase A as an autoantigen in a sub-group of patients with HMD, a clinically ill-defined syndrome. Anti-aldolase A antibodies may represent a useful biomarker of autoimmunity in HMD patients.",
keywords = "Aldolase A, Hyperkinetic movement disorders, SERPA",
author = "Daniela Privitera and Valeria Corti and Massimo Alessio and Antonietta Volont{\`e} and Vito Lampasona and Giancarlo Comi and Gianvito Martino and Diego Franciotta and Roberto Furlan and Raffaella Fazio",
year = "2013",
month = "3",
doi = "10.1007/s10072-012-0996-y",
language = "English",
volume = "34",
pages = "313--320",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders

AU - Privitera, Daniela

AU - Corti, Valeria

AU - Alessio, Massimo

AU - Volontè, Antonietta

AU - Lampasona, Vito

AU - Comi, Giancarlo

AU - Martino, Gianvito

AU - Franciotta, Diego

AU - Furlan, Roberto

AU - Fazio, Raffaella

PY - 2013/3

Y1 - 2013/3

N2 - We tried to identify the target/s of autoantibodies to basal ganglia neurons found in a patient with hyperkinetic movement disorders (HMD) characterized by rapid, rhythmic involuntary movements or spasms in both face and neck. Patient and control sera were used in Western blot to probe mouse brain homogenates. Two-dimensional gel electrophoresis (2-DE) SDS-PAGE protein spots recognized by the patient's antibodies were excised and sequenced by mass spectrometry analysis, and the glycolytic enzyme aldolase A was identified as the antigen recognized by the patient's autoantibodies. To assess relevance and specificity of these antibodies to the identified targets as biomarkers of autoimmunity in movement disorders, autoantibody responses to the identified target were then measured by ELISA in various diseases of the central nervous system. Anti-aldolase A autoantibodies were associated mainly with HMD (7/17, 41%) and Parkinson's disease (4/30, 13%) patients, and undetectable in subjects with other inflammatory and non-inflammatory central nervous system diseases. We, thus, identified aldolase A as an autoantigen in a sub-group of patients with HMD, a clinically ill-defined syndrome. Anti-aldolase A antibodies may represent a useful biomarker of autoimmunity in HMD patients.

AB - We tried to identify the target/s of autoantibodies to basal ganglia neurons found in a patient with hyperkinetic movement disorders (HMD) characterized by rapid, rhythmic involuntary movements or spasms in both face and neck. Patient and control sera were used in Western blot to probe mouse brain homogenates. Two-dimensional gel electrophoresis (2-DE) SDS-PAGE protein spots recognized by the patient's antibodies were excised and sequenced by mass spectrometry analysis, and the glycolytic enzyme aldolase A was identified as the antigen recognized by the patient's autoantibodies. To assess relevance and specificity of these antibodies to the identified targets as biomarkers of autoimmunity in movement disorders, autoantibody responses to the identified target were then measured by ELISA in various diseases of the central nervous system. Anti-aldolase A autoantibodies were associated mainly with HMD (7/17, 41%) and Parkinson's disease (4/30, 13%) patients, and undetectable in subjects with other inflammatory and non-inflammatory central nervous system diseases. We, thus, identified aldolase A as an autoantigen in a sub-group of patients with HMD, a clinically ill-defined syndrome. Anti-aldolase A antibodies may represent a useful biomarker of autoimmunity in HMD patients.

KW - Aldolase A

KW - Hyperkinetic movement disorders

KW - SERPA

UR - http://www.scopus.com/inward/record.url?scp=84879688716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879688716&partnerID=8YFLogxK

U2 - 10.1007/s10072-012-0996-y

DO - 10.1007/s10072-012-0996-y

M3 - Article

C2 - 22391679

AN - SCOPUS:84879688716

VL - 34

SP - 313

EP - 320

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 3

ER -